Results 111 to 120 of about 112,622 (301)

Construction of PANoptosis‐Inhibiting Carbonized Polymer Dots via Machine Learning Potential for Mitigating Chemodrug‐Induced Nephrotoxicity

Advanced Science, EarlyView.
An enhanced sampling method is developed for molecular dynamics based on trained machine learning force fields to guide the construction of PANoptosis‐inhibiting carbonized polymer dots (Lu‐CDs) derived from a flavonoid compound for treating chemodrug‐induced nephrotoxicity.
Xinchen Liu, Jiaxin Zhang, Xiangyu Yan, Nuo Li, Yu‐Chao Dong, Zihao Wang, Daowei Li, Yong Du, Huan Wang   +8 more
wiley   +1 more source

Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. [PDF]

, 2017
SHH Medulloblastoma (SHH-MB) is a pediatric brain tumor characterized by an inappropriate activation of the developmental Hedgehog (Hh) signaling. SHH-MB patients treated with the FDA-approved vismodegib, an Hh inhibitor that targets the transmembrane ...
Bufalieri, Francesca, Canettieri, Gianluca, Capalbo, Carlo, Coni, Sonia, DE SMAELE, Enrico, Di Magno, L, DI MARCOTULLIO, Lucia, Ferretti, Elisabetta, Kusio Kobialka, M, Mai, Antonello, Mancuso, ANNA BARBARA, Manni, Simona, Niewiadomski, P, Petroni, Marialaura, Rotili, Dante, Screpanti, Isabella, Sdruscia, Giulia, Serrao, SILVIA MARIA, Spiombi, Eleonora   +18 more
core   +2 more sources

Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

Advanced Science, EarlyView.
Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao, Qian Hao, Yu Gan, Jing Tong, Xiaodan Chen, Shuran Tan, Ruiwen Ruan, Yingdan Huang, Mingming Cao, Jun Deng, Tao Han, Getao Shi, Bo Gao, Yu Zhang, Xiang Zhou   +14 more
wiley   +1 more source

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging

EJNMMI Radiopharmacy and Chemistry
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising class of therapeutics, particularly in the treatment of cancers with defective DNA repair mechanisms, such as those with breast cancer genes (BRCA) mutations.
Gianluca Destro, Rebecca Rizzo, Chiara Rua, Raha Rouhbakhsh Azimi, Silvia Morbelli   +4 more
doaj   +1 more source

PARP inhibitor combinations in prostate cancer

Therapeutic Advances in Medical Oncology, 2020
Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms.
Carmel Pezaro
doaj   +1 more source

Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1 [PDF]

, 2014
DNA double-strand breaks (DSBs) are repaired by nonhomologous end joining (NHEJ) or homologous recombination (HR). The C terminal binding protein–interacting protein (CtIP) is phosphorylated in G2 by cyclin-dependent kinases to initiate resection and ...
Anantha, Anger, Bahassi, Beausoleil, Bernard S. Lopez, Beucher, Boboila, Bunting, Chapman, Chapman, Chen, Darroudi, Davis, de Cárcer, Deckbar, Di Virgilio, Donnianni, Elia, Escribano-Díaz, Feng, Golsteyn, Gotoh, Helmink, Huertas, Huertas, Jackman, Jackson, Jiadong Wang, Julia Künzel, Junjie Chen, Kim, Kühne, Lansing, Lee, Lee-Theilen, Li, Lin Feng, Lukas, Lukas, Löbrich, Mansour, Markus Löbrich, Mladenov, Monika Steinlage, Mosesso, Moynahan, Naim, Nakamura, Nodar Makharashvili, Nussenzweig, Nussenzweig, Olivia Barton, Panier, Pearce, Penny A. Jeggo, Peterson, Polo, Quennet, Rass, Reczek, Reinhardt, Rief, Ronja Diemer-Biehs, Rothkamm, Sandro Conrad, Sartori, Shibata, Steffen C. Naumann, Stephan, Tanya T. Paull, van Gent, van Gent, Wang, Wang, Wang, Weichert, Weichert, Weinstock, Ying, Yu, Yu, Yun, Zhang, Zimmerman, Zimmermann   +84 more
core   +1 more source

Spatio‐Temporal Proteomic Landscape Reveals Early Warning Signals of Esophageal Squamous Cell Carcinoma Progression

Advanced Science, EarlyView.
This study constructs a proteomic atlas of esophageal squamous cell carcinoma (ESCC) progression using esophageal biopsy samples. It identifies moderate dysplasia as the critical turning stage and a seven‐protein panel for early detection. Functionally, GBP6 loss promotes ESCC progression via cell cycle and epithelial‐mesenchymal transition (EMT ...
Xumiao Li, Jie Yuan, Min Gao, Jibin Liu, Qinqin Wang, Yaqi Zhang, Mingtao Cao, Xiaolin Hu, Hui Yang, Jun Li, Chen Li, Xiaoguang Li, Hui Wang   +12 more
wiley   +1 more source

SLC2A3‐Mediated Lactate Metabolism Promotes Lung Cancer Bone Metastasis by Modulating P53 Lactylation and Immune Evasion

Advanced Science, EarlyView.
SLC2A3 derived lactate promotes metastasis through p53 lactylation at K120 and osteoclast differentiation. Pharmacological inhibition of SLC2A3 upregulates PD‐1 expression on CD8+ T cells via lactate induced p53 lactylation, which modulates immune evasion. ABSTRACT Bone metastasis is a devastating consequence of lung cancer.
Yi Ding, Yuying Tian, Wenjie Ren, Xianglin Hu, Mengjuan Li, Bei Liu, Chen chen, Yunhan Lu, Lei Li, Wangjun Yan, Kun Li   +10 more
wiley   +1 more source

CRISPR‐Cas9‐Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real‐Time MRI Monitoring

Advanced Science, EarlyView.
This study identifies POLD4 as a potential prostate cancer radiosensitization target through transcriptome sequencing. By encapsulating POLD4‐targeted CRISPR/Cas9 plasmids and USPIONs in cationic liposomes, an MRI‐monitored gene‐editing platform is established.
Xuhui Fan, Ruru Zhang, Linjun Yang, Shixiong Chen, Meijuan He, Yongqiang Wang, Linjie Huang, Jianfeng Zeng, Shuwang Wu, Mingyuan Gao, Han Wang   +10 more
wiley   +1 more source

PARP inhibitors for prostate cancer

Seminars in Oncology
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread use of genomic testing in all patients with mCRPC.
Ossian Longoria, Nick Beije, Johann S. de Bono   +2 more
openaire   +2 more sources